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Abstract
Before a pathogen even enters a cell, intrinsic immune 
defenses are active. This first-line defense is mediated 
by a variety of constitutively expressed cell proteins 
collectively termed “restriction factors” (RFs), and they 
form a vital element of the immune response to virus 
infections. Over time, however, viruses have evolved in 
a variety ways so that they are able to overcome these 
RF defenses via  mechanisms that are specific for each 
virus. This review provides a summary of the universal 
characteristics of RFs, and goes on to focus on the 
strategies employed by some of the most important 
RFs in their attempt to control human cytomegalovirus 
(HCMV) infection. This is followed by a discussion of 
the counter-restriction mechanisms evolved by viruses 
to circumvent the host cell’s intrinsic immune defenses. 
RFs include nuclear proteins IFN-γ inducible protein 
16 (IFI16) (a Pyrin/HIN domain protein), Sp100, prom-
yelocytic leukemia, and hDaxx; the latter three being 
the keys elements of nuclear domain 10 (ND10). 
IFI16 inhibits the synthesis of virus DNA by down-
regulating UL54 transcription - a gene encoding a CMV 
DNA polymerase; in response, the virus antagonizes 
IFI16 via  a process involving viral proteins UL97 and 
pp65 (pUL83), which results in the mislocalizing of 
IFI16 into the cytoplasm. In contrast, viral regulatory 
proteins, including pp71 and IE1, seek to modify or 
disrupt the ND10 proteins and thus block or reverse 
their inhibitory effects upon virus replication. All in all, 
detailed knowledge of these HCMV counter-restriction 
mechanisms will be fundamental for the future 
development of new strategies for combating HCMV 
infection and for identifying novel therapeutic agents.
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Core tip: Cellular “restriction factors”, active before 
human cytomegalovirus (HCMV) enters the cells, form a 
component of the intrinsic resistance to virus infection. 
Examples of such factors are hDaxx, promyelocytic 
leukemia, Sp100 - components of ND10 - and IFN-γ 
inducible protein 16 (IFI16), an Interferon-inducible 
protein of the Pyrin/HIN domain protein family. Over 
time, viruses have developed mechanisms to counteract 
ND10 and IFI16 through viral proteins, such as IE1 
and pp71, or UL97 and pp65, respectively. Detailed 
knowledge of these mechanisms will provide new 
competencies useful to control HCMV infection and, in 
turn, contribute to the development of novel therapeutic 
approaches.
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INTRODUCTION
Viral replication in the infected cell is the result of 
complex interactions between host and viral proteins. 
Indeed, in the course of evolution, mammalian immune 
systems have evolved to response via an array of cellular 
defense mechanisms, which include both innate and 
adaptive immune responses, designed to protect against 
and remove invading pathogens[1]. The innate immune 
system, mediated by specialized cells such as natural 
killer cells (NK), dendritic cells, and macrophages[2], is 
the first to respond, but it is not very specific and does 
not lead to a long-lasting memory of the response 
to the pathogen. A specific form of innate immunity, 
termed “intrinsic immunity”, has also been identified 
of late, thus generating a third branch of the immune 
system that was until now considered a bipartite system. 
Intrinsic immunity involved a set of defense mechanisms 
that operate on the cellular level[3], realized by cellular 
proteins known as “restriction factors” (RFs), as they 
can interfere with various steps of the virus replication 
cycle[4,5]. The word restriction factor was first coined by 
research groups studying the murine immune response 
to retroviruses. Work conducted over 40 years ago 
revealed that “friend virus susceptibility factor-1” was 
responsible for conferring resistance to infection by 
retroviruses[6]. Retroviruses consequently became a 
model system for investigating intrinsic immunity and 
have been instrumental in deepening our knowledge of 
the interaction between viruses and their hosts[7,8]. Over 
time, the notion of “intrinsic immunity” get up from the 
finding that the cells attacked by primate lentiviruses are 
able to resist infection, despite the fact that no signaling 
event appeared to be necessary for this form of defense, 
and from the finding that these cells constitutively ex-
press prototype human antiretroviral RFs, including the 
APOBEC3 family of cytidine deaminases[9,10], TRIM5a[11], 
Tetherin[7], SAMHD1[12], and BST-2[13,14]. RFs are thus 
germline-encoded proteins mediating the intrinsic cellular 
immune response against viral replication. Type Ⅰinter-
ferons (IFN) have been demonstrated to increase the 
expression of RFs, however cells targeted by IFN do not 
rely on its activity for constitutive antiretroviral activity[15]. 
INTRINSIC IMMUNITY
The sensing of “pathogen-associated molecular patterns” 
(PAMPs) - typically microbe nucleic acids and proteins 
(usually absent from healthy hosts and thus hallmarks 
of infection) - by germline encoded proteins serving as 
“pattern recognition receptors” (PRRs) constitutes the 
earliest step in the innate immune response[2,16]. Viral 
nucleic acid including DNA containing CpG motifs, and 
RNA species, including both double-stranded and single-
stranded RNA, can be detected by Toll-like receptors 
TLR3, TLR7-8 and TLR9, or PRR in the cytoplasmatic 
or the nuclear compartment[17,18]. Two different innate 
immunity signaling cascades are triggered by detect-
ing exogenous nucleic acid. In the first, transcription 
factors (TFs) are activated, such as NF-kB and IRF3, 
culminating in the production of chemokines, cytokines, 
and IFN-type Ⅰ[19,20]. The second signaling cascade leads 
to inflammasome complex formation; this activates 
caspase-1, an enzyme that generates active cytokines 
set for secretion by proteolytically cutting pro-IL-1β 
and pro-IL-18[21-23]. Whereas PRRs activate signals 
that inhibit infection indirectly, RFs provide front-line 
defense by interfering directly with the activity of genes 
essential for the virus’s replication. Indeed, this is often 
computed before the production of antiviral cytokines 
has even been activated. Thus, the properties of RFs 
are clearly distinct to those of PRRs. First and foremost, 
while RFs are basally expressed in many cell types, their 
expression may be increased by IFN signaling. Second, 
isolated RFs have been shown to exhibit antiviral activity 
in cells, maintaining their capacity to inhibit precise steps 
in the viral life cycle. Third, viral proteins have evolved 
to antagonize certain RFs. Finally, genetic selection 
driven by host vs pathogen coevolution has undoubtedly 
operated on the genes for RFs[3]. Thus, according to the 
concept of intrinsic immunity, we can define cell as either 
“restrictive” or “permissive” depending on viruses ability 
to replicate efficiently within them[5,24]. Retroviruses 
have presented a model that has played a pivotal role 
in the development of our understanding of virus-host 
interactions[4,8,14,15,18]. However, evidence now shows that 
several other viruses are also counteracted by intrinsic 
immunity, including herpesviruses[25,26]. 
Here, we focus on the newest findings about human 
cytomegalovirus (HCMV), which belongs to the Her-
pesviridae family[27,28], and provide a summary of the RFs 
that perturb its replication (Table 1). Interestingly, HCMV 
appears to have evolved a number of mechanisms to 
counteract the action of restriction factors, ultimately 
leading to the successful replication of viruses in cells[29-32]. 
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THE IFN-γ INDUCIBLE PROTEIN 16 
PROTEIN
The IFN inducible IFI16 protein is a member of the Pyrin 
and HIN domain containing proteins (PYHIN) family; it 
is coded by an IFN-inducible group of genes residing on 
chromosome 1q23[33-35]. In humans, this family includes 
five PYHIN proteins: The recently discovered “Pyrin 
domain only protein 3”, “Pyrin and HIN domain family 
member 1” (PYHIN1), “absent in melanoma 2” (AIM2), 
“myeloid cell nuclear differentiation antigen” (MNDA), 
and “IFN-γ inducible protein 16” (IFI16)[36,37]. All five of 
these proteins possess an N-terminal PYRIN domain, and 
at least four possess a conserved domain of 200-amino 
acid repeats (HIN-200) within the C-terminal region 
(in single or tandem copies), thus they are collectively 
known as PYHIN. The PYD (or PAAD or DAPIN) domain is 
a member of the death domain family and consists of an 
α-helical motif that interacts with other PYD-containing 
proteins[38]. The HIN domain contains consensus motifs 
encompassing the 200-amino acid repeats, according 
to which it is classified into 3 subtypes, designated A, 
B, C[39,40]. PYHIN1, MNDA, and IFI16 all contain nuclear 
localization sequences located within their N-termini, and 
as such are primarily expressed in the cell nucleus[35,39,41]. 
However, in response to environmental stimuli, such 
as viral infection, they undergo post-translational modi-
fications, i.e., acetylation, and translocate into the 
cytoplasm[42,43]. Alternative splicing of the IFI16 gene 
produces three isoforms[39]; each isoform is made up 
of two domains, designated A and B, each 200-amino 
acid long. These domains are divided by a spacer 
region that may vary in its length. The B isoform is 
the most predominant and has been detected in an 
array of histologically distinct cell types (i.e., immune, 
endothelial, and epithelial cells[44]). The IFI16 N-terminal 
region display a bi-partite “nuclear localization signal”[45], 
responsible for its nuclear subcellular localization in 
quiescent cells, such as: Fibroblasts[46], endothelial cells, 
and keratinocytes (for a review see[47]). It is of interest 
that IFI16 protein has also been identified within the 
nucleolus[34]. However, in fibroblasts, macrophages, and 
keratinocytes, IFI16 is able to relocate from the nucleus 
to the cytoplasm. In fibroblasts and macrophages, this 
occurs following infection by herpesvirus[42,43]; while in 
keratinocytes, exposure to ultraviolet B light is able to 
trigger this redistribution[48,49]. In herpesvirus infection, 
IFI16 redistribution is associated with inflammasome, 
and after UVB exposure, it is associated with apoptosis. 
IFI16 is able to form homodimers or bind to other proteins 
to form heterodimers; its partners include: p53[38,50,51], 
Rb[52], BRCA1[53], ASC[54] and STING[55]. Indeed, protein-
protein interactions are now thought to determine the 
subcellular localization of proteins; however, the mole-
cular mechanisms regulating the redistribution of IFI16 
from the nuclear to the cytoplasmic compartment remain 
unknown. Finally, a role of viral DNA sensor has also 
been attributed to cytoplasmic IFI16[47,56]. Indeed, the 
capacity of IFI16 to bind to viral DNA has been confirmed 
both in vitro and in vivo[40,55-60]. It is now believed that 
IFI16 may actually tune the innate immune response by 
stimulating IFN-type Ⅰ release[47,56]. Thus, in addition to 
the various types of protein-protein interactions involving 
IFI16, another factor that may lead or contribute to IFI16 
redistribution within the cell is its binding to microbial DNA.
Inhibition of HCMV replication by IFI16 and viral evasion 
AIM2 and IFI16 are the two PYHIN members that 
have been demonstrated to act as PRRs of intracellular 
DNA of virus origin[51,60-66]. In particular, in cells infected 
with Kaposi Sarcoma Associated herpesvirus, IFI16 
was revealed to form a functional inflammasome by 
interacting with ASC together with procaspase-1[54]. 
Moreover, this virus triggered NF-kB and IRF3 expression 
and activation [TFs routinely observed to be activated 
Host restriction factors 
PYHIN family
Regulation CMV inhibition HCMV counter measure Ref.
IFI16 Type Ⅰ IFN inducible HCMV-DNA sensing in the nucleus
 
Sequestration by HCMV pp65 for 
MIEP activation
[42,43,46,60,72]
Interaction with HCMV pp65 to inhibit
UL54 promoter
Protection from proteasome 
degradation by pp65
Antiviral cytokine expression Delocalization upon 
phosphorylation by HCMV UL97
AIM2 Type Ⅰ IFN inducible MCMV-DNA sensing in the cytoplasm Not known [66]
Inflammasome activation
ND10 family
   PML Cell cycle dependent Transcriptionally inactive chromatin state of 
MIEP induction
Targeting HCMV IE1 for 
degradation
hDaxx binding by pp71 for 
proteasome degradation
[93-116]
   hDaxx
   Sp100
KDMs Cell cycle dependent Inhibition of HCMV latency Prevention of KDM association with 
the MIEP by HCMV UL138
[117]
Table 1  Overview of host restriction factors for human cytomegalovirus
CMV: Cytomegalovirus; HCMV: Human cytomegalovirus; MCMV: Murine cytomegalovirus; IFI16: IFN-γ inducible protein 16; PYHIN: Pyrin/HIN 
domain; AIM2: Absent in melanoma 2; KDMs: Lysine-specific demethylases; MIEP: Major immediate early promoter.
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after DNA transfection or the infection with herpes 
simplex virus type 1 (HSV-1)] could be inhibited by 
reducing IFI16 expression (or its mouse counterpart 
p204) using siRNA[67-70]. Besides its role as a PRR, IFI16 
had previously been recognized to carry out a variety 
of other functions in the cell, although none in relation 
to antiviral activity (reviewed in[35]). However, our 
understanding of the functions of IFI16 in the cell has 
dramatically changed over modern years; this is largely 
due to the results gained from the application of two 
different experimental approaches (reviewed in[42]). The 
first involves IFI16 knockdown through the use of specific 
siRNA or IFI16 inactivation achieved by transfecting cells 
with a lentivirus carrying a dominant negative mutant 
form of the protein[71]. For example, eliminating functional 
IFI16 protein in fibroblasts isolated from human embryo 
lung (HELFs), via either methodology, was shown to 
significantly increase herpesvirus replication, including 
HCMV. The second approach involves augmenting 
the quantity of IFI16. The overexpression of IFI16 in 
HELFs infected with HCMV was associated with a 2.5 
log reduction in viral yield. However, light had yet to be 
shed on the molecular mechanisms responsible for the 
antiviral role of IFI16, prompting an investigation into the 
consequences of overexpression on the distinct phases of 
virus replication. Exploiting the luciferase reporter gene 
methodology, transfection experiments were used to 
study the effects of deleting the viral polymerase (UL54) 
or UL44 promoters or introducing mutated forms of the 
two[72]. These studies indicated the IR-1 locus (inverted 
repeat element 1), located upstream of the polymerase 
transcription start-site, to be the object of IFI16-induced 
virus suppression. Chromatin immunoprecipitation and 
EMSA revealed that Sp1-like factors were effectively 
blocked by IFI16 and that this in turn led to UL54 sup-
pression. This result was confirmed by deleting the 
element within the UL44 promoter responsive to Sp1, 
which accordingly eliminated the suppressive effect of 
IFI16 on HCMV replication (UL44 protein associates with 
UL54 during viral DNA replication). Thus, in addition to 
confirming IFI16’s role as a DNA sensor, for the first time 
IFI16 had also been demonstrated to act as a restriction 
factor of herpesvirus replication[72] (Figure 1).
HCMV is nevertheless able to replicate in host cells 
despite the restrictive capacity of IFI16. This suggests 
that HCMV has developed evasion strategies to respond 
to the effects of IFI16[42,43]. The first evidence sustaining 
a plausible HCMV evasion strategy was obtained by 
infecting fibroblasts with a BAC mutant unable to express 
UL97 phosphoprotein[42]. Early on during infection, IFI16 
binds to virus DNA, but at a later time point during viral 
DNA synthesis, IFI16 undergoes relocalization from the 
nucleus to the cytoplasm. It was also revealed that this 
virus-induced movement of IFI16 out of the nucleus 
required that UL97 (a viral protein kinase) bound to 
IFI16. Upon binding to UL97 phosphoprotein, IFI16 
undergoes phosphorylation, which in turn promotes 
its nucleo-cytoplasmic relocalization. IFI16’s ensuing 
transfer into the virus assembly complex is regulated by 
the endosomal sorting complex required for transport 
machinery. Finally, IFI16 becomes integrated into newly 
assembled virions during the process of virus maturation 
and budding, effectively expelling IFI16 from the infected 
host[42]. However, recent studies have revealed that IFI16 
phosphorylation by UL97 is not the only mechanism 
for HCMV escape from IFI16 restriction activity. Using 
a BAC mutant virus unable to express the tegument 
protein pp65 (pUL83) Biolatti et al[73] (2016, unpublished 
results) have demonstrated that IFI16 interacts with 
pp65 targeting early gene promoters including that of 
the viral DNA polymerase pUL54. The capability of IFI16 
to downregulate virus growth was found to depend on its 
interaction with pp65 at the UL54 promoter, as shown by 
the growth properties of the HMCV mutant v65Stop in 
IFI16 knockdown cells. Interestingly, at later time points 
of HCMV infection, IFI16 was not degraded, as observed 
in HSV-1 - infected cells, but it was protected by its 
interaction with pp65. These data reveal a dual role for 
pp65. Initially it modulates IFI16 activity at the promoter 
of immediate-early and early genes, and subsequently, 
it delocalizes IFI16 from the nucleus, thereby protecting 
it from proteasomal degradation. Overall, these data 
identify a novel activity displayed by the pp65/IFI16 
interactome in the regulation of UL54 gene expression 
and IFI16 protein stability during HCMV replication.
In summary, these experiments point toward IFI16 
nuclear egression, subsequent to its binding to UL97 
and pp65, as the mechanism through which HCMV is 
successfully able to evade IFI16 restriction activity; 
this removal of IFI16 from its site of restriction activity 
is finalized with its incorporation into newly formed 
virions and expulsion from the cell altogether[42]. This is 
most likely the event that, to all intents and purposes, 
underlies the HMCV’s successful evasion of IFI16 an-
tiviral activity (Figure 1, Table 1).
NUCLEAR DOMAIN 10 
The nuclear matrix, hypothesized by some to organize and 
regulate a number of nuclear functions within the nucleus 
of eukaryotes[74,75], contains discrete bodies designated 
“nuclear domain 10” (ND10), “promyelocytic leukemia 
(PML) nuclear bodies”, or PODS. These bodies appear as 
sphere-like, measuring between 0.1-1 µm in diameter, 
and in some circumstances they present a granular 
center. ND10 can be found within the nucleoplasmic 
domains collectively termed the interchromosomal space, 
often next to proteinaceous bodies. Sp100, hDaxx, 
and PML protein are three of the protein constituents 
of ND10. These proteins recruit additional proteins that 
are SUMOylated[76,77]. One of these additional proteins is 
SUMO, a protein related to ubiquitin, and its conjugation 
to PML is implicated in the further recruitment of yet 
more binding partners[76,77]. ND10 are devoid of RNA or 
DNA and they typically gather into clusters of 5 to 15[78]. 
PML protein forms the outer “casing” of the structure, 
and its protein partners are usually concentrated inside. 
Functionally, ND10 play a regulatory role, influencing 
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diverse key processes, such as DNA damage repair[79], 
oncogenesis[80-82], apoptosis[83-85], senescence[86,87], and 
gene expression regulation[75,76]. The fact that ND10 are 
subject to profound biochemical modification during 
virus infection is of particular interest[81,87-90]. During the 
infection of quiescent cells, evidence indicates that NB10 
accumulates viral DNA within their central core and/or at 
their periphery. Moreover, considering the fact that IFNs 
stimulate an increase expression of PML, hDaxx, and 
Sp100[91-93], it would appear that ND10 play a key role in 
the innate antiviral response. 
ND10 restriction of HCMV replication vs viral evasion 
tactics
Although aggregates of HCMV IE gene transcripts only 
form adjacent to ND10 - originally considered the ideal 
cellular location for HCMV to initiate its program of IE 
gene expression - it was soon realized that early during 
infection HCMV actually targets ND10 in order to destroy 
them[94-97] (Figure 1, Table 1). The viral regulatory protein 
IE1 is responsible for this activity; moreover ND10 
destruction by IE1 correlates with efficient lytic repli-
cation[98]. ND10 are now understood to be key cellular 
restriction factors playing an effective biological role in 
the inhibition of virus replication. The silencing of PML 
expression by siRNA and thus depletion of this ND10 
constituent, for instance, was shown to increase the 
susceptibility of “human primary foreskin fibroblasts” 
(HFF) to HCMV infection[92]. Indeed, the capacity of ND10 
bodies to restrict HCMV is achieved by down-regulating 
IE gene expression[93]. Of note, when PML-null HFF 
were used, HCMV infection resulted in the formation 
of Sp100 and hDaxx[99]. It has since emerged that it is 
actually the virus itself that stimulates the recruitment of 
ND10 constituents to nucleoprotein complex of HCMV[98]. 
What is more, studies suggest that this ND10-instigated 
intrinsic immune response probably entails other ND10 
associated proteins, like Sp100 and hDaxx[100-102]. 
In summary, the results of studies carried out by 
various groups together depict a scenario where all the 
three key ND10 proteins - i.e., Sp100, hDaxx, and PML- 
are involved in restricting viral replication through the 
silencing of viral IE gene expression[97,102-104]. In addition, 
infection experiments comparing the effects of single 
vs double knock-down of ND10 constituents found that 
HCMV gene expression was actually lower in the single 
knock-down cells compared with the respective double 
knock-down conditions[101,102]. This undoubtedly points 
toward the individual proteins playing independent roles 
in HCMV restriction. Epigenetic mechanisms able to 
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Figure 1  Simplified model of host restrictions against human cytomegalovirus and mechanisms of viral escape. IFI16 recognizes HCMV-DNA in the nucleus. 
In the early phases of infection, HCMV-pp65 hijacks IFI16 to activate MIEP expression; later on the complex IFI16-pp65 blocks HCMV replication by inhibiting the 
action of Sp1 on UL54 promoter. IFI16 is not degraded, but it was stabilized by its interaction with pp65. To evade IFI16 antiviral activity, HCMV induces nuclear 
translocation of IFI16 upon recruitment of HCMV kinase UL97 to IFI16. In the cytoplasm, IFI16 activates STING-mediated antiviral cytokine expression. ND10 
components (hDaxx, Sp100, PML) limit viral replication by silencing viral IE genes, inducing a transcriptionally inactive chromatin state of the MIEP via recruitment of 
ATRX or HDACs to the viral DNA. The viral pp71 binds to hDaxx for proteasome degradation and relieves MIEP repression. Degradation of hDaxx is preceded by the 
release of ATRX from ND10. IE1 promotes the dispersion of the ND10, by de-SUMOylation, with the consequent inhibition of PML oligomerization. HCMV: Human 
cytomegalovirus; IFI16: IFN-γ inducible protein 16; PYHIN: Pyrin/HIN domain; AIM2: Absent in melanoma 2; MIEP: Major immediate early promoter; ND10: Nuclear 
domain 10; ATRX: Alpha thalassemia and mental retardation syndrome X-linked; PML: Promyelocytic leukemia.
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block viral genome transcription and replication may be 
involved[105,106]. During early infection, viral DNA exists in 
a repressive chromatin state, a result of posttranslational 
modifications of histones[106]. Through its ability to recruit 
to the viral DNA chromatin modifying enzymes, including 
the histone deacetylases, or chromatin remodeling protein 
“alpha thalassemia and mental retardation syndrome 
X-linked” (ATRX)[105,107], hDaxx has been demonstrated to 
convert the HCMV immediate-early enhancer/promoter 
(MIEP) into a transcriptionally inactive chromatin state[108]. 
Sp100 and PML have similarly been confirmed to interact 
with enzymes that modify chromatin; once again im-
plicating the contribution of possible epigenetic modi-
fications in the intrinsic immune repression of IE gene 
expression[109,110]. 
Until now, the role of ND10 has largely been studied 
in the context of productive HCMV infection. Interestingly, 
Saffert and Kalejta[110], using three different cellular 
settings, including NT2 and THP-1 cells, primary human 
CD34+ cells, and two myeloblastic cell lines (Kasumi-3 
and KG-1), provided evidence that hDaxx is also 
involved in IE gene silencing in latent HCMV infections. 
By contrast, the group led by Sinclair provide evidence 
indicating that hDaxx protein is only marginally involved 
in MIEP regulation during latent infection, since its 
knockdown in NT2 cells block IE gene expression[105]. To 
solve this apparent discrepancy, Stamminger’s group[111] 
used the THP-1 monocytes recognized as reliable in 
vitro latency model of HCMV. In non-differentiated 
THP-1 monocytes, HCMV undergoes latency; while in 
THP-1 cells induced to undergo differentiation towards a 
macrophage-like phenotype, achieved using PMA, HCMV 
enters its lytic cycle[111]. The results obtained showed 
that the silencing of PML, hDaxx, or Sp100 expression 
by small hairpin RNA in non-differentiated THP-1 mono-
cytes did not have an effect on IE gene expression. In 
contrast, the silencing of ND10 in differentiated THP-1 
significantly augmented cells positive for IE gene ex-
pression. Altogether, these conclusions indicate that 
hDaxx, PML, and Sp100 serve as restriction factors of IE 
gene expression, but are only marginally involved in the 
establishment of HCMV latency[111]. 
Nevertheless, we know that HCMV is still able to 
undergo successful lytic replication in spite of the restric-
tive behavior of the ND10 constituent proteins; this 
tells us that HCMV has co-evolved to circumvent this 
aspect of the innate immune response. Indeed, we now 
know that shortly after virus penetration, pp71 (the viral 
transactivator tegument protein) moves to ND10 bodies 
where it interacts with ND10 constituent proteins[112]; in 
particular, it associates with hDaxx, which, as discussed 
above, is capable of down-regulating IE gene expression 
by silencing MIEP[113]. The interaction between pp71 
and hDaxx results in the latter being directed down the 
path of proteasome degradation, thereby relieving MIEP 
repression[112]. However, investigations by other groups 
have recently shown that the scenario is actually much 
more complex. Degradation of hDaxx is preceded by the 
pp71-stimulated release of ATRX from ND10, and it is 
the displacement of ATRX that alleviates the repression 
of IE gene expression[113]. 
While pp71 is fundamental to counteract the capa-
city of both ATRX and hDaxx to silence virus genes, it 
is the action of IE1 protein that seems to eliminate the 
restrictive effects of PML protein. Indeed, IEI stimulates 
ND10 body dispersal, with the associated displacement 
of both PML and Sp100. At low MOI, IE1 synergizes with 
IE2 and promotes the activation of various viral gene 
expression[114,115]. However, only IE1 is required for ND10 
dispersal. Moreover, the disruption of PML by IE1 is not 
followed by degradation of PML via proteosome; instead 
it becomes de-SUMOylated; which effectively inhibits 
PML oligomerization and thus its ability to re-associate 
within ND10 bodies[116] (Figure 1, Table 1). 
LYSINE-SPECIFIC DEMETHYLASES
Lysine-specific demethylases (KDMs) inhibit the esta-
blishment of HCMV latency by getting rid of epigenetic 
“tags” present on histones associated with the repression 
of MIEP. Interestingly, the viral UL138 protein counteracts 
this defense by interfering with the association of KDMs 
with the MIEP[117] (Table 1). 
Thus, the presence of viral factors neutralizing cog-
nate host restriction factors indicate that HCMV has 
developed multiple escape strategies over lifelong coloni-
zation at the cellular level.
CONCLUSION
In conclusion, frontline cell defense against HCMV re-
plication is now known to be accomplished by different 
proteins through different pathways. Moreover, the viral 
countermeasures to overcome these restriction factors 
are now clearly understood to involve a number of viral 
proteins, including pp71, IE1, UL97, and pp65. Ongoing 
research is presently being focused at compiling a more 
in-depth picture of the molecular mechanisms involving 
ND10 that underlie the host cell’s restrictive response 
the viral evasion strategies. 
REFERENCES
1 McCormick AL, Mocarski ES. Viral modulation of the host response 
to infection. In: Arvin A, Campadelli­Fiume G, Mocarski E, Moore 
PS, Roizman B, Whitley R, Yamanishi K. Human Herpesviruses: 
Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge 
University Press. [accessed 2016 Apr 19]. Available from: URL: 
http//www.ncbi.nlm.nih.gov/books/NBK47417
2 Takeuchi O, Akira S. Pattern recognition receptors and inflam­
mation. Cell 2010; 140: 805­820 [PMID: 20303872 DOI: 10.1016/
j.cell.2010.01.022]
3 Bieniasz PD. Intrinsic immunity: a front­line defense against viral 
attack. Nat Immunol 2004; 5: 1109­1115 [PMID: 15496950 DOI: 
10.1038/ni1125]
4 Bieniasz PD. Restriction factors: a defense against retroviral infec­
tion. Trends Microbiol 2003; 11: 286­291 [PMID: 12823946]
5 Johnson WE. Rapid adversarial co­evolution of viruses and cellular 
restriction factors. Curr Top Microbiol Immunol 2013; 371: 123­151 
Landolfo S et al . Restriction factors of HCMV replication
93 August 12, 2016|Volume 5|Issue 3|WJV|www.wjgnet.com
[PMID: 23686234 DOI: 10.1007/978­3­642­37765­5_5]
6 Pincus T, Rowe WP, Lilly F. A major genetic locus affecting 
resistance to infection with murine leukemia viruses. II. Apparent 
identity to a major locus described for resistance to friend murine 
leukemia virus. J Exp Med 1971; 133: 1234­1241 [PMID: 4325133]
7 Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release 
and is antagonized by HIV­1 Vpu. Nature 2008; 451: 425­430 
[PMID: 18200009 DOI: 10.1038/nature06553]
8 Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV­1 
and mechanisms of viral escape. Nat Immunol 2015; 16: 546­553 
[PMID: 25988886 DOI: 10.1038/ni.3156]
9 Compton AA, Hirsch VM, Emerman M. The host restriction factor 
APOBEC3G and retroviral Vif protein coevolve due to ongoing 
genetic conflict. Cell Host Microbe 2012; 11: 91­98 [PMID: 
22264516 DOI: 10.1016/j.chom.2011.11.010]
10 Malim MH. APOBEC proteins and intrinsic resistance to HIV­1 
infection. Philos Trans R Soc Lond B Biol Sci 2009; 364: 675­687 
[PMID: 19038776 DOI: 10.1098/rstb.2008.0185]
11 Grütter MG, Luban J. TRIM5 structure, HIV­1 capsid recognition, 
and innate immune signaling. Curr Opin Virol 2012; 2: 142­150 
[PMID: 22482711 DOI: 10.1016/j.coviro.2012.02.003]
12 Yan J, Kaur S, DeLucia M, Hao C, Mehrens J, Wang C, Golczak 
M, Palczewski K, Gronenborn AM, Ahn J, Skowronski J. Tetra­
merization of SAMHD1 is required for biological activity and 
inhibition of HIV infection. J Biol Chem 2013; 288: 10406­10417 
[PMID: 23426366 DOI: 10.1074/jbc.M112.443796]
13 Hammonds J, Wang JJ, Spearman P. Restriction of Retroviral 
Replication by Tetherin/BST­2. Mol Biol Int 2012; 2012: 424768 
[PMID: 22811908 DOI: 10.1155/2012/424768]
14 Jakobsen MR, Olagnier D, Hiscott J. Innate immune sensing of 
HIV­1 infection. Curr Opin HIV AIDS 2015; 10: 96­102 [PMID: 
25485569 DOI: 10.1097/COH.0000000000000129]
15 Neil S, Bieniasz P. Human immunodeficiency virus, restriction 
factors, and interferon. J Interferon Cytokine Res 2009; 29: 569­580 
[PMID: 19694548 DOI: 10.1089/jir.2009.0077]
16 Mogensen TH. Pathogen recognition and inflammatory signaling 
in innate immune defenses. Clin Microbiol Rev 2009; 22: 240­73, 
Table of Contents [PMID: 19366914 DOI: 10.1128/CMR.00046­08]
17 Thaiss CA, Levy M, Itav S, Elinav E. Integration of Innate Immune 
Signaling. Trends Immunol 2016; 37: 84­101 [PMID: 26755064 
DOI: 10.1016/j.it.2015.12.003]
18 Thompson MR, Kaminski JJ, Kurt­Jones EA, Fitzgerald KA. 
Pattern recognition receptors and the innate immune response to 
viral infection. Viruses 2011; 3: 920­940 [PMID: 21994762 DOI: 
10.3390/v3060920]
19 Paludan SR, Bowie AG. Immune sensing of DNA. Immunity 
2013; 38: 870­880 [PMID: 23706668 DOI: 10.1016/j.immuni. 
2013.05.004]
20 Unterholzner L. The interferon response to intracellular DNA: why 
so many receptors? Immunobiology 2013; 218: 1312­1321 [PMID: 
23962476 DOI: 10.1016/j.imbio.2013.07.007]
21 Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of 
action, role in disease, and therapeutics. Nat Med 2015; 21: 677­687 
[PMID: 26121197 DOI: 10.1038/nm.3893]
22 Latz E, Xiao TS, Stutz A. Activation and regulation of the inflam­
masomes. Nat Rev Immunol 2013; 13: 397­411 [PMID: 23702978 
DOI: 10.1038/nri3452]
23 Xiao TS. The nucleic acid­sensing inflammasomes. Immunol Rev 
2015; 265: 103­111 [PMID: 25879287 DOI: 10.1111/imr.12281]
24 Dempsey A, Bowie AG. Innate immune recognition of DNA: A 
recent history. Virology 2015; 479-480: 146­152 [PMID: 25816762 
DOI: 10.1016/j.virol.2015.03.013]
25 Diner BA, Lum KK, Cristea IM. The emerging role of nuclear 
viral DNA sensors. J Biol Chem 2015; 290: 26412­26421 [PMID: 
26354430 DOI: 10.1074/jbc.R115.652289]
26 Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition 
of herpesviruses by the innate immune system. Nat Rev Immunol 
2011; 11: 143­154 [PMID: 21267015 DOI: 10.1038/nri2937]
27 Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, 
and puzzle. J Clin Invest 2011; 121: 1673­1680 [PMID: 21659716 
DOI: 10.1172/JCI45449]
28 Griffiths P, Baraniak I, Reeves M. The pathogenesis of human 
cytomegalovirus. J Pathol 2015; 235: 288­297 [PMID: 25205255 
DOI: 10.1002/path.4437]
29 Beck K, Meyer­König U, Weidmann M, Nern C, Hufert FT. Human 
cytomegalovirus impairs dendritic cell function: a novel mechanism 
of human cytomegalovirus immune escape. Eur J Immunol 2003; 
33: 1528­1538 [PMID: 12778470 DOI: 10.1002/eji.200323612]
30 Browne EP, Shenk T. Human cytomegalovirus UL83­coded 
pp65 virion protein inhibits antiviral gene expression in infected 
cells. Proc Natl Acad Sci USA 2003; 100: 11439­11444 [PMID: 
12972646 DOI: 10.1073/pnas.1534570100]
31 Child SJ, Hakki M, De Niro KL, Geballe AP. Evasion of cellular 
antiviral responses by human cytomegalovirus TRS1 and IRS1. J 
Virol 2004; 78: 197­205 [PMID: 14671101]
32 Marshall EE, Geballe AP. Multifaceted evasion of the interferon 
response by cytomegalovirus. J Interferon Cytokine Res 2009; 29: 
609­619 [PMID: 19708810 DOI: 10.1089/jir.2009.0064]
33 Trapani JA, Dawson M, Apostolidis VA, Browne KA. Genomic 
organization of IFI16, an interferon­inducible gene whose expression 
is associated with human myeloid cell differentiation: correlation of 
predicted protein domains with exon organization. Immunogenetics 
1994; 40: 415­424 [PMID: 7959953]
34 Dawson MJ, Trapani JA. The interferon­inducible autoantigen, 
IFI 16: localization to the nucleolus and identification of a DNA­
binding domain. Biochem Biophys Res Commun 1995; 214: 
152­162 [PMID: 7545391 DOI: 10.1006/bbrc.1995.2269]
35 Gariglio M, Mondini M, De Andrea M, Landolfo S. The multi­
faceted interferon­inducible p200 family proteins: from cell 
biology to human pathology. J Interferon Cytokine Res 2011; 31: 
159­172 [PMID: 21198352 DOI: 10.1089/jir.2010.0106]
36 Connolly DJ, Bowie AG. The emerging role of human PYHIN 
proteins in innate immunity: implications for health and disease. 
Biochem Pharmacol 2014; 92: 405­414 [PMID: 25199457 DOI: 
10.1016/j.bcp.2014.08.031]
37 Jakobsen MR, Paludan SR. IFI16: At the interphase between 
innate DNA sensing and genome regulation. Cytokine Growth 
Factor Rev 2014; 25: 649­655 [PMID: 25027602 DOI: 10.1016/
j.cytogfr.2014.06.004]
38 Liao JC, Lam R, Brazda V, Duan S, Ravichandran M, Ma J, 
Xiao T, Tempel W, Zuo X, Wang YX, Chirgadze NY, Arrowsmith 
CH. Interferon­inducible protein 16: insight into the interaction 
with tumor suppressor p53. Structure 2011; 19: 418­429 [PMID: 
21397192 DOI: 10.1016/j.str.2010.12.015]
39 Johnstone RW, Kershaw MH, Trapani JA. Isotypic variants of the 
interferon­inducible transcriptional repressor IFI 16 arise through 
differential mRNA splicing. Biochemistry 1998; 37: 11924­11931 
[PMID: 9718316 DOI: 10.1021/bi981069a]
40 Jin T, Perry A, Jiang J, Smith P, Curry JA, Unterholzner L, Jiang 
Z, Horvath G, Rathinam VA, Johnstone RW, Hornung V, Latz E, 
Bowie AG, Fitzgerald KA, Xiao TS. Structures of the HIN domain: 
DNA complexes reveal ligand binding and activation mechanisms 
of the AIM2 inflammasome and IFI16 receptor. Immunity 2012; 36: 
561­571 [PMID: 22483801 DOI: 10.1016/j.immuni.2012.02.014]
41 Gariglio M, Azzimonti B, Pagano M, Palestro G, De Andrea M, 
Valente G, Voglino G, Navino L, Landolfo S. Immunohistochemical 
expression analysis of the human interferon­inducible gene IFI16, 
a member of the HIN200 family, not restricted to hematopoietic 
cells. J Interferon Cytokine Res 2002; 22: 815­821 [PMID: 
12184920 DOI: 10.1089/107999002320271413]
42 Dell’Oste V, Gatti D, Gugliesi F, De Andrea M, Bawadekar M, Lo 
Cigno I, Biolatti M, Vallino M, Marschall M, Gariglio M, Landolfo 
S. Innate nuclear sensor IFI16 translocates into the cytoplasm 
during the early stage of in vitro human cytomegalovirus infection 
and is entrapped in the egressing virions during the late stage. 
J Virol 2014; 88: 6970­6982 [PMID: 24696486 DOI: 10.1128/
JVI.00384­14]
43 Li T, Diner BA, Chen J, Cristea IM. Acetylation modulates cellular 
distribution and DNA sensing ability of interferon­inducible 
protein IFI16. Proc Natl Acad Sci USA 2012; 109: 10558­10563 
Landolfo S et al . Restriction factors of HCMV replication
94 August 12, 2016|Volume 5|Issue 3|WJV|www.wjgnet.com
[PMID: 22691496 DOI: 10.1073/pnas.1203447109]
44 Wei W, Clarke CJ, Somers GR, Cresswell KS, Loveland KA, 
Trapani JA, Johnstone RW. Expression of IFI 16 in epithelial 
cells and lymphoid tissues. Histochem Cell Biol 2003; 119: 45­54 
[PMID: 12548405 DOI: 10.1007/s00418­002­0485­0]
45 Briggs LJ, Johnstone RW, Elliot RM, Xiao CY, Dawson M, 
Trapani JA, Jans DA. Novel properties of the protein kinase CK2­
site­regulated nuclear­ localization sequence of the interferon­
induced nuclear factor IFI 16. Biochem J 2001; 353: 69­77 [PMID: 
11115400]
46 Cristea IM, Moorman NJ, Terhune SS, Cuevas CD, O’Keefe ES, 
Rout MP, Chait BT, Shenk T. Human cytomegalovirus pUL83 
stimulates activity of the viral immediate­early promoter through 
its interaction with the cellular IFI16 protein. J Virol 2010; 84: 
7803­7814 [PMID: 20504932 DOI: 10.1128/JVI.00139­10]
47 Veeranki S, Choubey D. Interferon­inducible p200­family 
protein IFI16, an innate immune sensor for cytosolic and nuclear 
double­stranded DNA: regulation of subcellular localization. Mol 
Immunol 2012; 49: 567­571 [PMID: 22137500 DOI: 10.1016/
j.molimm.2011.11.004]
48 Bawadekar M, De Andrea M, Gariglio M, Landolfo S. Mislo­
calization of the interferon inducible protein IFI16 by enviro­
nmental insults: implications in autoimmunity. Cytokine Growth 
Factor Rev 2015; 26: 213­219 [PMID: 25466628 DOI: 10.1016/
j.cytogfr.2014.10.003]
49 Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, Berti 
E, Gariglio M, Landolfo S. Redistribution of the nuclear protein 
IFI16 into the cytoplasm of ultraviolet B­exposed keratinocytes as 
a mechanism of autoantigen processing. Br J Dermatol 2011; 164: 
282­290 [PMID: 20973769 DOI: 10.1111/j.1365­2133.2010.10097.x]
50 Gugliesi F, Mondini M, Ravera R, Robotti A, de Andrea M, 
Gribaudo G, Gariglio M, Landolfo S. Up­regulation of the in­
terferon­inducible IFI16 gene by oxidative stress triggers p53 
transcriptional activity in endothelial cells. J Leukoc Biol 2005; 77: 
820­829 [PMID: 15728246 DOI: 10.1189/jlb.0904507]
51 Johnstone RW, Wei W, Greenway A, Trapani JA. Functional 
interaction between p53 and the interferon­inducible nucleoprotein 
IFI 16. Oncogene 2000; 19: 6033­6042 [PMID: 11146555 DOI: 
10.1038/sj.onc.1204005]
52 Xin H, Curry J, Johnstone RW, Nickoloff BJ, Choubey D. Role of 
IFI 16, a member of the interferon­inducible p200­protein family, 
in prostate epithelial cellular senescence. Oncogene 2003; 22: 
4831­4840 [PMID: 12894224 DOI: 10.1038/sj.onc.1206754]
53 Aglipay JA, Lee SW, Okada S, Fujiuchi N, Ohtsuka T, Kwak JC, 
Wang Y, Johnstone RW, Deng C, Qin J, Ouchi T. A member of the 
Pyrin family, IFI16, is a novel BRCA1­associated protein involved 
in the p53­mediated apoptosis pathway. Oncogene 2003; 22: 
8931­8938 [PMID: 14654789 DOI: 10.1038/sj.onc.1207057]
54 Kerur N, Veettil MV, Sharma­Walia N, Bottero V, Sadagopan S, 
Otageri P, Chandran B. IFI16 acts as a nuclear pathogen sensor to 
induce the inflammasome in response to Kaposi Sarcoma­associated 
herpesvirus infection. Cell Host Microbe 2011; 9: 363­375 [PMID: 
21575908 DOI: 10.1016/j.chom.2011.04.008]
55 Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, 
Sharma S, Sirois CM, Jin T, Latz E, Xiao TS, Fitzgerald KA, 
Paludan SR, Bowie AG. IFI16 is an innate immune sensor for 
intracellular DNA. Nat Immunol 2010; 11: 997­1004 [PMID: 
20890285 DOI: 10.1038/ni.1932]
56 Brázda V, Coufal J, Liao JC, Arrowsmith CH. Preferential binding 
of IFI16 protein to cruciform structure and superhelical DNA. 
Biochem Biophys Res Commun 2012; 422: 716­720 [PMID: 
22618232 DOI: 10.1016/j.bbrc.2012.05.065]
57 Ni X, Ru H, Ma F, Zhao L, Shaw N, Feng Y, Ding W, Gong W, 
Wang Q, Ouyang S, Cheng G, Liu ZJ. New insights into the 
structural basis of DNA recognition by HINa and HINb domains 
of IFI16. J Mol Cell Biol 2016; 8: 51­61 [PMID: 26246511 DOI: 
10.1093/jmcb/mjv053]
58 Sharma S, DeOliveira RB, Kalantari P, Parroche P, Goutagny N, 
Jiang Z, Chan J, Bartholomeu DC, Lauw F, Hall JP, Barber GN, 
Gazzinelli RT, Fitzgerald KA, Golenbock DT. Innate immune 
recognition of an AT­rich stem­loop DNA motif in the Plasmodium 
falciparum genome. Immunity 2011; 35: 194­207 [PMID: 
21820332 DOI: 10.1016/j.immuni.2011.05.016]
59 Stratmann SA, Morrone SR, van Oijen AM, Sohn J. The innate 
immune sensor IFI16 recognizes foreign DNA in the nucleus by 
scanning along the duplex. Elife 2015; 4: e11721 [PMID: 26673078 
DOI: 10.7554/eLife.11721]
60 Horan KA, Hansen K, Jakobsen MR, Holm CK, Søby S, 
Unterholzner L, Thompson M, West JA, Iversen MB, Rasmussen 
SB, Ellermann­Eriksen S, Kurt­Jones E, Landolfo S, Damania B, 
Melchjorsen J, Bowie AG, Fitzgerald KA, Paludan SR. Proteasomal 
degradation of herpes simplex virus capsids in macrophages 
releases DNA to the cytosol for recognition by DNA sensors. J 
Immunol 2013; 190: 2311­2319 [PMID: 23345332 DOI: 10.4049/
jimmunol.1202749]
61 Ansari MA, Singh VV, Dutta S, Veettil MV, Dutta D, Chikoti L, Lu 
J, Everly D, Chandran B. Constitutive interferon­inducible protein 
16­inflammasome activation during Epstein­Barr virus latency I, II, 
and III in B and epithelial cells. J Virol 2013; 87: 8606­8623 [PMID: 
23720728 DOI: 10.1128/JVI.00805­13]
62 Johnson KE, Chikoti L, Chandran B. Herpes simplex virus 1 
infection induces activation and subsequent inhibition of the IFI16 
and NLRP3 inflammasomes. J Virol 2013; 87: 5005­5018 [PMID: 
23427152 DOI: 10.1128/JVI.00082­13]
63 Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, 
Tengchuan J, Laustsen A, Hansen K, Ostergaard L, Fitzgerald KA, 
Xiao TS, Mikkelsen JG, Mogensen TH, Paludan SR. IFI16 senses 
DNA forms of the lentiviral replication cycle and controls HIV­1 
replication. Proc Natl Acad Sci USA 2013; 110: E4571­80 [PMID: 
24154727 DOI: 10.1073/pnas.1311669110]
64 Lo Cigno I, De Andrea M, Borgogna C, Albertini S, Landini MM, 
Peretti A, Johnson KE, Chandran B, Landolfo S, Gariglio M. The 
Nuclear DNA Sensor IFI16 Acts as a Restriction Factor for Human 
Papillomavirus Replication through Epigenetic Modifications 
of the Viral Promoters. J Virol 2015; 89: 7506­7520 [PMID: 
25972554 DOI: 10.1128/JVI.00013­15]
65 Man SM, Karki R, Kanneganti TD. AIM2 inflammasome in 
infection, cancer, and autoimmunity: Role in DNA sensing, 
inflammation, and innate immunity. Eur J Immunol 2016; 46: 
269­280 [PMID: 26626159 DOI: 10.1002/eji.201545839]
66 Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, 
Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung 
V, Vogel SN, Szomolanyi­Tsuda E, Fitzgerald KA. The AIM2 
inflammasome is essential for host defense against cytosolic 
bacteria and DNA viruses. Nat Immunol 2010; 11: 395­402 [PMID: 
20351692 DOI: 10.1038/ni.1864]
67 Conrady CD, Zheng M, Fitzgerald KA, Liu C, Carr DJ. Resistance 
to HSV­1 infection in the epithelium resides with the novel innate 
sensor, IFI­16. Mucosal Immunol 2012; 5: 173­183 [PMID: 
22236996 DOI: 10.1038/mi.2011.63]
68 Orzalli MH, DeLuca NA, Knipe DM. Nuclear IFI16 induction of 
IRF­3 signaling during herpesviral infection and degradation of 
IFI16 by the viral ICP0 protein. Proc Natl Acad Sci USA 2012; 109: 
E3008­E3017 [PMID: 23027953 DOI: 10.1073/pnas.1211302109]
69 Orzalli MH, Conwell SE, Berrios C, DeCaprio JA, Knipe DM. 
Nuclear interferon­inducible protein 16 promotes silencing of 
herpesviral and transfected DNA. Proc Natl Acad Sci USA 2013; 110: 
E4492­E4501 [PMID: 24198334 DOI: 10.1073/pnas.1316194110]
70 Søby S, Laursen RR, Ostergaard L, Melchjorsen J. HSV­1­induced 
chemokine expression via IFI16­dependent and IFI16­independent 
pathways in human monocyte­derived macrophages. Herpesviridae 
2012; 3: 6 [PMID: 23062757 DOI: 10.1186/2042­4280­3­6]
71 Gariano GR, Dell’Oste V, Bronzini M, Gatti D, Luganini A, De 
Andrea M, Gribaudo G, Gariglio M, Landolfo S. The intracellular 
DNA sensor IFI16 gene acts as restriction factor for human 
cytomegalovirus replication. PLoS Pathog 2012; 8: e1002498 
[PMID: 22291595 DOI: 10.1371/journal.ppat.1002498]
72 Rivera-Molina YA, Martínez FP, Tang Q. Nuclear domain 10 of 
the viral aspect. World J Virol 2013; 2: 110­122 [PMID: 24255882 
DOI: 10.5501/wjv.v2.i3.110]
Landolfo S et al . Restriction factors of HCMV replication
95 August 12, 2016|Volume 5|Issue 3|WJV|www.wjgnet.com
73 Biolatti M, Dell'Oste V, Pautasso S, von Einem J, Marschall M, 
Plachter B, Gariglio M, De Andrea M, Landolfo S. Regulatory 
Interaction between the Cellular Restriction Factor IFI16 and Viral 
pp65 (pUL83) Modulates Viral Gene Expression and IFI16 Protein 
Stability. J Virol 2016; Epub ahead of print [PMID: 27384655 DOI: 
10.1128/JVI.00923­16]
74 Stuurman N, Meijne AM, van der Pol AJ, de Jong L, van Driel R, 
van Renswoude J. The nuclear matrix from cells of different origin. 
Evidence for a common set of matrix proteins. J Biol Chem 1990; 
265: 5460­5465 [PMID: 2180926]
75 Bernardi R, Pandolfi PP. Structure, dynamics and functions of 
promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 
2007; 8: 1006­1016 [PMID: 17928811 DOI: 10.1038/nrm2277]
76 Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The 
mechanisms of PML­nuclear body formation. Mol Cell 2006; 24: 
331­339 [PMID: 17081985 DOI: 10.1016/j.molcel.2006.09.013]
77 Boisvert FM, Hendzel MJ, Bazett­Jones DP. Promyelocytic 
leukemia (PML) nuclear bodies are protein structures that do 
not accumulate RNA. J Cell Biol 2000; 148: 283­292 [PMID: 
10648561]
78 Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush 
LJ, Verbel DA, Cordon­Cardo C, Pandolfi PP. Loss of the tumor 
suppressor PML in human cancers of multiple histologic origins. J 
Natl Cancer Inst 2004; 96: 269­279 [PMID: 14970276]
79 Koken MH, Linares­Cruz G, Quignon F, Viron A, Chelbi­Alix 
MK, Sobczak­Thépot J, Juhlin L, Degos L, Calvo F, de Thé H. 
The PML growth­suppressor has an altered expression in human 
oncogenesis. Oncogene 1995; 10: 1315­1324 [PMID: 7731682]
80 Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Hénin D, 
Dejean A. PML nuclear bodies are general targets for inflammation 
and cell proliferation. Cancer Res 1995; 55: 1590­1597 [PMID: 
7882370]
81 Everett RD. Interactions between DNA viruses, ND10 and the 
DNA damage response. Cell Microbiol 2006; 8: 365­374 [PMID: 
16469050 DOI: 10.1111/j.1462­5822.2005.00677.x]
82 Bernardi R, Pandolfi PP. Role of PML and the PML­nuclear 
body in the control of programmed cell death. Oncogene 2003; 22: 
9048­9057 [PMID: 14663483 DOI: 10.1038/sj.onc.1207106]
83 Bernardi R, Papa A, Pandolfi PP. Regulation of apoptosis by 
PML and the PML­NBs. Oncogene 2008; 27: 6299­6312 [PMID: 
18931695 DOI: 10.1038/onc.2008.305]
84 Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP. 
The function of PML in p53­dependent apoptosis. Nat Cell Biol 
2000; 2: 730­736 [PMID: 11025664 DOI: 10.1038/35036365]
85 Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean 
A. Deconstructing PML­induced premature senescence. EMBO 
J 2002; 21: 3358­3369 [PMID: 12093737 DOI: 10.1093/emboj/
cdf341]
86 Salomoni P, Pandolfi PP. The role of PML in tumor suppression. 
Cell 2002; 108: 165­170 [PMID: 11832207]
87 Carvalho T, Seeler JS, Ohman K, Jordan P, Pettersson U, 
Akusjärvi G, Carmo­Fonseca M, Dejean A. Targeting of adenovirus 
E1A and E4­ORF3 proteins to nuclear matrix­associated PML 
bodies. J Cell Biol 1995; 131: 45­56 [PMID: 7559785]
88 Everett RD. DNA viruses and viral proteins that interact with PML 
nuclear bodies. Oncogene 2001; 20: 7266­7273 [PMID: 11704855 
DOI: 10.1038/sj.onc.1204759]
89 Maul GG, Guldner HH, Spivack JG. Modification of discrete 
nuclear domains induced by herpes simplex virus type 1 immediate 
early gene 1 product (ICP0). J Gen Virol 1993; 74 (Pt 12): 
2679­2690 [PMID: 8277273 DOI: 10.1099/0022­1317­74­12­2679]
90 Szekely L, Pokrovskaja K, Jiang WQ, de The H, Ringertz N, 
Klein G. The Epstein­Barr virus­encoded nuclear antigen EBNA­5 
accumulates in PML­containing bodies. J Virol 1996; 70: 2562­2568 
[PMID: 8642686]
91 Negorev DG, Vladimirova OV, Maul GG. Differential functions 
of interferon­upregulated Sp100 isoforms: herpes simplex virus 
type 1 promoter­based immediate­early gene suppression and PML 
protection from ICP0­mediated degradation. J Virol 2009; 83: 
5168­5180 [PMID: 19279115 DOI: 10.1128/JVI.02083­08]
92 Regad T, Chelbi­Alix MK. Role and fate of PML nuclear bodies 
in response to interferon and viral infections. Oncogene 2001; 20: 
7274­7286 [PMID: 11704856 DOI: 10.1038/sj.onc.1204854]
93 Ahn JH, Hayward GS. The major immediate­early proteins IE1 
and IE2 of human cytomegalovirus colocalize with and disrupt 
PML­associated nuclear bodies at very early times in infected 
permissive cells. J Virol 1997; 71: 4599­4613 [PMID: 9151854]
94 Kelly C, Van Driel R, Wilkinson GW. Disruption of PML­
associated nuclear bodies during human cytomegalovirus infection. 
J Gen Virol 1995; 76 (Pt 11): 2887­2893 [PMID: 7595400 DOI: 
10.1099/0022­1317­76­11­2887]
95 Kim YE, Lee JH, Kim ET, Shin HJ, Gu SY, Seol HS, Ling PD, Lee 
CH, Ahn JH. Human cytomegalovirus infection causes degradation 
of Sp100 proteins that suppress viral gene expression. J Virol 2011; 
85: 11928­11937 [PMID: 21880768 DOI: 10.1128/JVI.00758­11]
96 Tavalai N, Adler M, Scherer M, Riedl Y, Stamminger T. Evidence 
for a dual antiviral role of the major nuclear domain 10 component 
Sp100 during the immediate­early and late phases of the human 
cytomegalovirus replication cycle. J Virol 2011; 85: 9447­9458 
[PMID: 21734036 DOI: 10.1128/JVI.00870­11]
97 Korioth F, Maul GG, Plachter B, Stamminger T, Frey J. The nuclear 
domain 10 (ND10) is disrupted by the human cytomegalovirus gene 
product IE1. Exp Cell Res 1996; 229: 155­158 [PMID: 8940259 DOI: 
10.1006/excr.1996.0353]
98 Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. Evidence 
for a role of the cellular ND10 protein PML in mediating intrinsic 
immunity against human cytomegalovirus infections. J Virol 2006; 
80: 8006­8018 [PMID: 16873257 DOI: 10.1128/JVI.00743­06]
99 Glass M, Everett RD. Components of promyelocytic leukemia 
nuclear bodies (ND10) act cooperatively to repress herpesvirus 
infection. J Virol 2013; 87: 2174­2185 [PMID: 23221561 DOI: 
10.1128/JVI.02950­12]
100 Tavalai N, Stamminger T. New insights into the role of the sub­
nuclear structure ND10 for viral infection. Biochim Biophys 
Acta 2008; 1783: 2207­2221 [PMID: 18775455 DOI: 10.1016/
j.bbamcr.2008.08.004]
101 Tavalai N, Papior P, Rechter S, Stamminger T. Nuclear domain 
10 components promyelocytic leukemia protein and hDaxx 
independently contribute to an intrinsic antiviral defense against 
human cytomegalovirus infection. J Virol 2008; 82: 126­137 
[PMID: 17942542 DOI: 10.1128/JVI.01685­07]
102 Adler M, Tavalai N, Müller R, Stamminger T. Human cytome­
galovirus immediate­early gene expression is restricted by the 
nuclear domain 10 component Sp100. J Gen Virol 2011; 92: 
1532­1538 [PMID: 21471311 DOI: 10.1099/vir.0.030981­0]
103 Everett RD, Chelbi­Alix MK. PML and PML nuclear bodies: 
implications in antiviral defence. Biochimie 2007; 89: 819­830 
[PMID: 17343971 DOI: 10.1016/j.biochi.2007.01.004]
104 Lukashchuk V, McFarlane S, Everett RD, Preston CM. Human 
cytomegalovirus protein pp71 displaces the chromatin­associated 
factor ATRX from nuclear domain 10 at early stages of infection. 
J Virol 2008; 82: 12543­12554 [PMID: 18922870 DOI: 10.1128/
JVI.01215­08]
105 Woodhall DL, Groves IJ, Reeves MB, Wilkinson G, Sinclair JH. 
Human Daxx­mediated repression of human cytomegalovirus gene 
expression correlates with a repressive chromatin structure around 
the major immediate early promoter. J Biol Chem 2006; 281: 
37652­37660 [PMID: 17035242 DOI: 10.1074/jbc.M604273200]
106 Preston CM, Nicholl MJ. Role of the cellular protein hDaxx 
in human cytomegalovirus immediate­early gene expression. J 
Gen Virol 2006; 87: 1113­1121 [PMID: 16603511 DOI: 10.1099/
vir.0.81566­0]
107 Reeves M, Woodhall D, Compton T, Sinclair J. Human cytome­
galovirus IE72 protein interacts with the transcriptional repressor 
hDaxx to regulate LUNA gene expression during lytic infection. 
J Virol 2010; 84: 7185­7194 [PMID: 20444888 DOI: 10.1128/
JVI.02231­09]
108 Kim EJ, Park JI, Nelkin BD. IFI16 is an essential mediator of 
growth inhibition, but not differentiation, induced by the leukemia 
inhibitory factor/JAK/STAT pathway in medullary thyroid 
Landolfo S et al . Restriction factors of HCMV replication
96 August 12, 2016|Volume 5|Issue 3|WJV|www.wjgnet.com
carcinoma cells. J Biol Chem 2005; 280: 4913­4920 [PMID: 
15572361 DOI: 10.1074/jbc.M410542200]
109 Shin HJ, Kim YE, Kim ET, Ahn JH. The chromatin­tethering 
domain of human cytomegalovirus immediate­early (IE) 1 mediates 
associations of IE1, PML and STAT2 with mitotic chromosomes, 
but is not essential for viral replication. J Gen Virol 2012; 93: 
716­721 [PMID: 22158879 DOI: 10.1099/vir.0.037986­0]
110 Saffert RT, Kalejta RF. Inactivating a cellular intrinsic immune 
defense mediated by Daxx is the mechanism through which the 
human cytomegalovirus pp71 protein stimulates viral immediate­
early gene expression. J Virol 2006; 80: 3863­3871 [PMID: 
16571803 DOI: 10.1128/JVI.80.8.3863­3871.2006]
111 Wagenknecht N, Reuter N, Scherer M, Reichel A, Müller R, 
Stamminger T. Contribution of the Major ND10 Proteins PML, 
hDaxx and Sp100 to the Regulation of Human Cytomegalovirus 
Latency and Lytic Replication in the Monocytic Cell Line THP­1. 
Viruses 2015; 7: 2884­2907 [PMID: 26057166 DOI: 10.3390/
v7062751]
112 Hofmann H, Sindre H, Stamminger T. Functional interaction 
between the pp71 protein of human cytomegalovirus and the PML­
interacting protein human Daxx. J Virol 2002; 76: 5769­5783 
[PMID: 11992005]
113 Cantrell SR, Bresnahan WA. Interaction between the human 
cytomegalovirus UL82 gene product (pp71) and hDaxx regulates 
immediate­early gene expression and viral replication. J Virol 
2005; 79: 7792­7802 [PMID: 15919932 DOI: 10.1128/JVI.79.12.7
792­7802.2005]
114 Greaves RF, Mocarski ES. Defective growth correlates with 
reduced accumulation of a viral DNA replication protein after low­
multiplicity infection by a human cytomegalovirus ie1 mutant. J 
Virol 1998; 72: 366­379 [PMID: 9420235]
115 Gawn JM, Greaves RF. Absence of IE1 p72 protein function during 
low­multiplicity infection by human cytomegalovirus results in a 
broad block to viral delayed­early gene expression. J Virol 2002; 
76: 4441­4455 [PMID: 11932411]
116 Xu Y, Ahn JH, Cheng M, apRhys CM, Chiou CJ, Zong J, Matunis 
MJ, Hayward GS. Proteasome­independent disruption of PML 
oncogenic domains (PODs), but not covalent modification by 
SUMO­1, is required for human cytomegalovirus immediate­early 
protein IE1 to inhibit PML­mediated transcriptional repression. 
J Virol 2001; 75: 10683­10695 [PMID: 11602710 DOI: 10.1128/
JVI.75.22.10683­10695.2001]
117 Lee SH, Albright ER, Lee JH, Jacobs D, Kalejta RF. Cellular defense 
against latent colonization foiled by human cytomegalovirus UL138 
protein. Sci Adv 2015; 1: e1501164 [PMID: 26702450 DOI: 10.1126/
sciadv.1501164]
P- Reviewer: Chan CH, Roohvand F    S- Editor: Qiu S 
L- Editor: A    E- Editor: Li D
Landolfo S et al . Restriction factors of HCMV replication
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
